Table 1 Demographic and laboratory findings in the control and CLL groups
From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
Variables | Entire population N = 83 | CLL group N = 42 | Control group N = 41 | p |
|---|---|---|---|---|
Age (years) | 62.8 ± 10.0 | 63.9 ± 9.8 | 61.7 ± 10.2 | 0.326 |
Gender | ||||
Female | 39 (47.0) | 14 (33.3) | 25 (61.0) | 0.016* |
Male | 44 (53.0) | 28 (66.7) | 16 (39.0) | |
Haemoglobin (g/dL) | 12.6 ± 2.1 | 12.5 ± 2.2 | 12.7 ± 2.0 | 0.707 |
WBCs (×103/μL) | 13.7 (2.6–131) | 27.1 (5.8–131) | 7.7 (2.6–16.3) | < 0.001* |
Neutrophils (×103/μL) | 4.7 (0.6–11.7) | 5.5 (0.6–11.5) | 4.6 (1.9–11.7) | 0.078 |
Lymphocytes (×103/μL) | 5 (0.4–123) | 21.3 (5–123) | 2.1 (0.4–4.1) | < 0.001* |
Platelets (×103/μL) | 225 (24–630) | 200 (24–463) | 253 (49–630) | 0.008* |
ELABELA (ng/ml) | 4.6 (0.1–19.7) | 6.7 (0.6–19.7) | 2 (0.1–8.6) | < 0.001* |